Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
<h4>Background</h4>Overexpression of RRM1 and RRM2 has been associated with gemcitabine resistance. BRCA1 overexpression increases sensitivity to paclitaxel and docetaxel. We have retrospectively examined the effect of RRM1, RRM2 and BRCA1 expression on outcome to gemcitabine plus doceta...
Guardado en:
Autores principales: | Ioannis Boukovinas, Chara Papadaki, Pedro Mendez, Miquel Taron, Dimitris Mavroudis, Anastasios Koutsopoulos, Maria Sanchez-Ronco, Jose Javier Sanchez, Maria Trypaki, Eustathios Staphopoulos, Vassilis Georgoulias, Rafael Rosell, John Souglakos |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2d8e5149519d416eb3ee0b6442ee0a97 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells.
por: Tomotaka Kato, et al.
Publicado: (2021) -
A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.
por: Jun Zhou, et al.
Publicado: (2013) -
Expression patterns and prognostic significances of RRM1 and ERCC1 in pancreatic carcinoma and cholangiocarcinoma
por: Khushbu Khetan, et al.
Publicado: (2021) -
Rrm2b deletion causes mitochondrial metabolic defects in renal tubules
por: Yi-Fan Chen, et al.
Publicado: (2019) -
Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.
por: Xiaopeng Dong, et al.
Publicado: (2014)